Nelly Jinga, Karl-Günter Technau, Kate Clouse, Nkosinathi Ngcobo, Cornelius Nattey, Candice Hwang, Anna Grimsrud, Amy Wise, Nicola van Dongen, Thalia Ferreira, Maanda Mudau, Mhairi Maskew
{"title":"Uptake and timing of viral load testing and frequency of viraemic episodes during pregnancy in South Africa.","authors":"Nelly Jinga, Karl-Günter Technau, Kate Clouse, Nkosinathi Ngcobo, Cornelius Nattey, Candice Hwang, Anna Grimsrud, Amy Wise, Nicola van Dongen, Thalia Ferreira, Maanda Mudau, Mhairi Maskew","doi":"10.1101/2025.03.19.25324178","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Repeated monitoring of viral load (VL) among pregnant women living with HIV (WLWH) is critical in vertical transmission prevention. For women who are newly diagnosed with HIV during pregnancy, a subsequent VL is recommended three months after ART initiation, and for all women living with HIV, follow-up VL is required every six months throughout pregnancy and breastfeeding [2]. Here, we describe the uptake and timing of VL testing and frequency and distribution of viraemic episodes during pregnancy.</p><p><strong>Methods: </strong>We linked prospective cohort data from WLWH whose infants were born at Rahima Moosa Mother and Child Hospital (RMMCH) in Johannesburg, South Africa (2013-2018) to laboratory data from the National Health Laboratory Services national HIV cohort. We report the uptake and timing of VL testing, and frequency of viremia and viral suppression. We also explore factors associated with having at least one or more VL test.</p><p><strong>Results: </strong>Data from 4,064 women with known dates of entry into antenatal care and delivery during the study period were analysed. Overall, less than half (46%) completed VL testing during pregnancy. Most VL were conducted during the third trimester (67%). Only 5% (n=100) were during the first trimester and 11% within 7 days of delivery. Three-quarters of tests during pregnancy indicated viral suppression (VL <400 copies/mL), 7% viraemic (VL 400-1000 copies/mL), and 19% high grade viraemia (VL >1000 copies/mL). We found that being older (≥35) and being engaged in HIV care prior to pregnancy were significantly associated with VL testing during pregnancy.</p><p><strong>Conclusion: </strong>With less than half of pregnant women living with HIV in this study having a VL measure during their pregnancy, and VL testing occurring late in pregnancy, this study highlights critical gaps in providing quality HIV care to women and prevention of vertical transmission.</p>","PeriodicalId":94281,"journal":{"name":"medRxiv : the preprint server for health sciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11957086/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv : the preprint server for health sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2025.03.19.25324178","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Repeated monitoring of viral load (VL) among pregnant women living with HIV (WLWH) is critical in vertical transmission prevention. For women who are newly diagnosed with HIV during pregnancy, a subsequent VL is recommended three months after ART initiation, and for all women living with HIV, follow-up VL is required every six months throughout pregnancy and breastfeeding [2]. Here, we describe the uptake and timing of VL testing and frequency and distribution of viraemic episodes during pregnancy.
Methods: We linked prospective cohort data from WLWH whose infants were born at Rahima Moosa Mother and Child Hospital (RMMCH) in Johannesburg, South Africa (2013-2018) to laboratory data from the National Health Laboratory Services national HIV cohort. We report the uptake and timing of VL testing, and frequency of viremia and viral suppression. We also explore factors associated with having at least one or more VL test.
Results: Data from 4,064 women with known dates of entry into antenatal care and delivery during the study period were analysed. Overall, less than half (46%) completed VL testing during pregnancy. Most VL were conducted during the third trimester (67%). Only 5% (n=100) were during the first trimester and 11% within 7 days of delivery. Three-quarters of tests during pregnancy indicated viral suppression (VL <400 copies/mL), 7% viraemic (VL 400-1000 copies/mL), and 19% high grade viraemia (VL >1000 copies/mL). We found that being older (≥35) and being engaged in HIV care prior to pregnancy were significantly associated with VL testing during pregnancy.
Conclusion: With less than half of pregnant women living with HIV in this study having a VL measure during their pregnancy, and VL testing occurring late in pregnancy, this study highlights critical gaps in providing quality HIV care to women and prevention of vertical transmission.